



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 1 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 1. Identification

**GHS product identifier** : Norepinephrine Bitartrate Injection, 4mg/4ml

**Other means of identification** : Not available.

**Product type** : Liquid.

### Relevant identified uses of the substance or mixture and uses advised against

**Product use** : Pharmaceuticals. (For intended use only.)  
Observe technical data sheet/instructions for use.  
Specific Treatments: vasoconstriction / blood pressure elevation

**Area of application** : Professional applications.

## Section 2. Hazards identification

**OSHA/HCS status** : While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

**Classification of the substance or mixture** : Not classified.

### GHS label elements

**Signal word** : No signal word.

**Hazard statements** : No known significant effects or critical hazards.

### Precautionary statements

**Prevention** : Not applicable.

**Response** : Not applicable.

**Storage** : Not applicable.

**Disposal** : Not applicable.

**Hazards not otherwise classified** : None known.

**Hazards identified when used** : No known significant effects or critical hazards.

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 2 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 3. Composition/information on ingredients

**Substance/mixture** : Mixture  
**Other means of identification** : Not available.

| Ingredient name           | Synonyms | %         | Identifiers      |
|---------------------------|----------|-----------|------------------|
| Water                     | -        | ≥80       | CAS: 7732-18-5   |
| sodium chloride           | -        | ≥0.1 - ≤1 | CAS: 7647-14-5   |
| Norepinephrine bitartrate | -        | ≥0.1 - ≤1 | CAS: 108341-18-0 |
| sodium metabisulphite     | -        | ≥0.1 - ≤1 | CAS: 7681-57-4   |

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

**There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified and hence require reporting in this section.**

## Section 4. First aid measures

### Description of necessary first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

### Most important symptoms/effects, acute and delayed

#### Potential acute health effects

- Eye contact** : No known significant effects or critical hazards.
- Inhalation** : No known significant effects or critical hazards.
- Skin contact** : No known significant effects or critical hazards.
- Ingestion** : No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

### Indication of immediate medical attention and special treatment needed, if necessary

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 3 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 4. First aid measures

- Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Specific treatments** : No specific treatment.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

## Section 5. Fire-fighting measures

### Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : Do not use water jet.

- Specific hazards arising from the chemical** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous thermal decomposition products** : No specific data.

- Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

## Section 6. Accidental release measures

### Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- Environmental precautions** : Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### Methods and materials for containment and cleaning up

- Small spill** : Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 4 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 6. Accidental release measures

- Large spill** : Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

## Section 7. Handling and storage

### Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

- Conditions for safe storage, including any incompatibilities** : Store between the following temperatures: 15 to 30°C (59 to 86°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

## Section 8. Exposure controls/personal protection

### Control parameters

#### Occupational exposure limits

| <b>Ingredient name</b>    | <b>Exposure limits</b>                                                                                                                                                                                                                                      |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Water                     | None.                                                                                                                                                                                                                                                       |
| sodium chloride           | None.                                                                                                                                                                                                                                                       |
| Norepinephrine bitartrate | None.                                                                                                                                                                                                                                                       |
| sodium metabisulphite     | <b>ACGIH TLV (United States, 1/2025) A4.</b><br>TWA 8 hours: 5 mg/m <sup>3</sup> .<br><b>NIOSH REL (United States, 10/2020)</b><br>TWA 10 hours: 5 mg/m <sup>3</sup> .<br><b>CAL OSHA PEL (United States, 1/2025)</b><br>TWA 8 hours: 5 mg/m <sup>3</sup> . |

### Biological exposure indices

None known.

- Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 5 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 8. Exposure controls/personal protection

**Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### Individual protection measures

**Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

### Skin protection

**Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

**Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

## Section 9. Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### Appearance

**Physical state** : Liquid. [Clear.]

**Color** : Colorless to light yellow.

**Odor** : Not available.

**Odor threshold** : Not available.

**pH** : 3 to 4.5

**Melting point** : Not available.

**Boiling point or initial** : Not available.

**boiling point and boiling range**

**Flash point** : Not available.

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 6 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 9. Physical and chemical properties

**Evaporation rate** : Not available.

**Flammability** : Not available.

**Lower and upper explosion limit/flammability limit** : Not available.

| Vapor pressure | Vapor Pressure at 20°C |       |     | Vapor pressure at 50°C |        |      |
|----------------|------------------------|-------|-----|------------------------|--------|------|
|                | Ingredient name        | mm Hg | kPa | Method                 | mm Hg  | kPa  |
|                | Water                  | 17.5  | 2.3 |                        | 92.258 | 12.3 |

**Relative vapor density** : Not available.

**Relative density** : Not available.

**Density** : 0.978 to 1.038 g/cm<sup>3</sup>

**Solubility(ies)** : Not available.

**Partition coefficient: n-octanol/water** : Not applicable.

**Auto-ignition temperature** : Not available.

**Decomposition temperature** : Not available.

**SADT** : Not available.

**Viscosity** : Dynamic (room temperature): Not available.  
Kinematic (room temperature): Not available.  
Kinematic (40°C (104°F)): Not available.

### Particle characteristics

**Median particle size** : Not applicable.

### Other information

**Physical/chemical properties comments** : No additional information.

## Section 10. Stability and reactivity

**Reactivity** : No specific test data related to reactivity available for this product or its ingredients.

**Chemical stability** : The product is stable.

**Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.  
Under normal conditions of storage and use, hazardous polymerization will not occur.

**Conditions to avoid** : No specific data.

**Incompatible materials** : No specific data.

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 7 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 10. Stability and reactivity

**Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## Section 11. Toxicological information

### Information on toxicological effects

#### Acute toxicity

##### Product/ingredient name

sodium chloride

##### Result

**Rat - Oral - LD50**

3000 mg/kg

Norepinephrine bitartrate

**Rat - Oral - LD50**

20 mg/kg

sodium metabisulphite

**Rat - Oral - LD50**

1131 mg/kg

Toxic effects: Behavioral - Food intake (animal) Behavioral - Muscle weakness Other - Hair

##### Conclusion/Summary [Product]

: Not available.

#### Skin corrosion/irritation

##### Product/ingredient name

sodium chloride

##### Result

**Rabbit - Skin - Mild irritant**

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 500 mg

##### Conclusion/Summary [Product]

: Not available.

#### Serious eye damage/eye irritation

##### Product/ingredient name

sodium chloride

##### Result

**Rabbit - Eyes - Moderate irritant**

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 100 mg

**Rabbit - Eyes - Moderate irritant**

Amount/concentration applied: 10 mg

sodium metabisulphite

**Rabbit - Eyes - Mild irritant**

Duration of treatment/exposure: 24 hours

Amount/concentration applied: 100 mg

##### Conclusion/Summary [Product]

: Not available.



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 8 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 11. Toxicological information

### Respiratory corrosion/irritation

**Conclusion/Summary [Product]** : Not available.

### Respiratory or skin sensitization

#### **Skin**

**Conclusion/Summary [Product]** : Not available.

#### **Respiratory**

**Conclusion/Summary [Product]** : Not available.

### Germ cell mutagenicity

**Conclusion/Summary [Product]** : Not available.

### Carcinogenicity

**Conclusion/Summary [Product]** : Not available.

### Classification

| Product/ingredient name | OSHA | IARC | NTP |
|-------------------------|------|------|-----|
| sodium metabisulphite   | -    | 3    | -   |

### Reproductive toxicity

**Conclusion/Summary [Product]** : Not available.

### Specific target organ toxicity (single exposure)

Not available.

### Specific target organ toxicity (repeated exposure)

Not available.

### Aspiration hazard

Not available.

### Information on the likely routes of exposure

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

|                                                                                     |                                        |                                     |
|-------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 9 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0       |

## Section 11. Toxicological information

Not available.

### Potential acute health effects

|                     |                                                     |
|---------------------|-----------------------------------------------------|
| <b>Eye contact</b>  | : No known significant effects or critical hazards. |
| <b>Inhalation</b>   | : No known significant effects or critical hazards. |
| <b>Skin contact</b> | : No known significant effects or critical hazards. |
| <b>Ingestion</b>    | : No known significant effects or critical hazards. |

### Symptoms related to the physical, chemical and toxicological characteristics

|                     |                     |
|---------------------|---------------------|
| <b>Eye contact</b>  | : No specific data. |
| <b>Inhalation</b>   | : No specific data. |
| <b>Skin contact</b> | : No specific data. |
| <b>Ingestion</b>    | : No specific data. |

### Delayed and immediate effects and also chronic effects from short and long term exposure

#### **Short term exposure**

|                                    |                  |
|------------------------------------|------------------|
| <b>Potential immediate effects</b> | : Not available. |
| <b>Potential delayed effects</b>   | : Not available. |

#### **Long term exposure**

|                                    |                  |
|------------------------------------|------------------|
| <b>Potential immediate effects</b> | : Not available. |
| <b>Potential delayed effects</b>   | : Not available. |

### Potential chronic health effects

**Conclusion/Summary [Product]** : Not available.

|                              |                                                     |
|------------------------------|-----------------------------------------------------|
| <b>General</b>               | : No known significant effects or critical hazards. |
| <b>Carcinogenicity</b>       | : No known significant effects or critical hazards. |
| <b>Mutagenicity</b>          | : No known significant effects or critical hazards. |
| <b>Reproductive toxicity</b> | : No known significant effects or critical hazards. |

### Numerical measures of toxicity

#### **Acute toxicity estimates**

|                                                                                     |                                        |                                      |
|-------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 10 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0        |

## Section 11. Toxicological information

| Product/ingredient name   | Oral (mg/kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapors) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|---------------------------|--------------|----------------|--------------------------|----------------------------|-------------------------------------|
| sodium chloride           | 3000         | N/A            | N/A                      | N/A                        | N/A                                 |
| Norepinephrine bitartrate | 20           | N/A            | N/A                      | N/A                        | N/A                                 |
| sodium metabisulphite     | 1131         | N/A            | N/A                      | N/A                        | N/A                                 |

## Section 12. Ecological information

### Toxicity

#### Product/ingredient name

sodium chloride

#### Result

##### Acute - LC50 - Fresh water

Fish - Striped bass - *Morone saxatilis* - Larvae  
1000 mg/l [96 hours]

Effect: Mortality

##### Chronic - NOEC - Fresh water

Daphnia - Water flea - *Daphnia pulex*  
0.314 g/l [21 days]

Effect: Reproduction

##### Chronic - NOEC - Fresh water

Fish - Eastern mosquitofish - *Gambusia holbrooki* - Adult  
100 mg/l [8 weeks]

Effect: Reproduction

##### Chronic - NOEC - Fresh water

Aquatic plants - Duckweed - *Lemna minor*  
6 g/l [96 hours]

Effect: Growth  
OECD

##### Acute - EC50 - Fresh water

Algae - Green algae - *Chlamydomonas reinhardtii*  
4.74 g/l [96 hours]

Effect: Population

##### Acute - EC50 - Fresh water

Daphnia - Water flea - *Daphnia magna*  
402.6 mg/l [48 hours]

Effect: Intoxication

Norepinephrine bitartrate

##### Acute - LC50

Fish  
>100 mg/l [96 hours]

sodium metabisulphite

##### Acute - LC50 - Fresh water

Fish - Bluegill - *Lepomis macrochirus*  
Size: 2.8 cm  
32 mg/l [96 hours]

Effect: Mortality

#### Conclusion/Summary [Product]

: Not available.

### Persistence and degradability

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

|                                                                                     |                                        |                                      |
|-------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 11 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0        |

## Section 12. Ecological information

**Conclusion/Summary [Product]** : Not available.

### Bioaccumulative potential

| Product/ingredient name | LogP <sub>ow</sub> | BCF | Potential |
|-------------------------|--------------------|-----|-----------|
| Water                   | -1.38              | -   | Low       |
| sodium metabisulphite   | -3.7               | -   | Low       |

### Mobility in soil

**Soil/Water partition coefficient** : Not available.

### Other adverse effects

No known significant effects or critical hazards.

## Section 13. Disposal considerations

**Disposal methods** : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

## Section 14. Transport information

|                                   | DOT Classification | IMDG           | IATA           |
|-----------------------------------|--------------------|----------------|----------------|
| <b>UN number</b>                  | Not regulated.     | Not regulated. | Not regulated. |
| <b>UN proper shipping name</b>    | -                  | -              | -              |
| <b>Transport hazard class(es)</b> | -                  | -              | -              |
| <b>Packing group</b>              | -                  | -              | -              |
| <b>Environmental hazards</b>      | No.                | No.            | No.            |



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

|                                                                                     |                                        |                                      |
|-------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 12 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0        |

## Section 14. Transport information

### Additional information

**Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**Transport in bulk according to IMO instruments** : Not available.

## Section 15. Regulatory information

**U.S. Federal regulations** : **TSCA 8(a) PAIR:** sodium metabisulphite  
**TSCA 8(a) CDR Exempt/Partial exemption:** Not determined  
**United States inventory (TSCA 8b):** All components are active or exempted.

### TSCA 12(b) - Chemical export notification

Not applicable.

**Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs)** : Not listed

**Clean Air Act Section 602 Class I Substances** : Not listed

**Clean Air Act Section 602 Class II Substances** : Not listed

**DEA List I Chemicals (Precursor Chemicals)** : Not listed

**DEA List II Chemicals (Essential Chemicals)** : Not listed

### SARA 302/304

#### Composition/information on ingredients

No products were found.

**SARA 304 RQ** : Not applicable.

### SARA 311/312

**Classification** : Not applicable.

#### Composition/information on ingredients



Meitheal Pharmaceuticals, Inc.

Safety Data Sheet

|                                                                                     |                                        |                                      |
|-------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 13 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0        |

## Section 15. Regulatory information

| Name                      | %         | Classification                                                        |
|---------------------------|-----------|-----------------------------------------------------------------------|
| sodium chloride           | ≥0.1 - ≤1 | EYE IRRITATION - Category 2A                                          |
| Norepinephrine bitartrate | ≥0.1 - ≤1 | ACUTE TOXICITY (oral) - Category 2<br>SKIN IRRITATION - Category 2    |
| sodium metabisulphite     | ≥0.1 - ≤1 | ACUTE TOXICITY (oral) - Category 4<br>SERIOUS EYE DAMAGE - Category 1 |

### SARA 313

Not applicable.

### State regulations

|                      |                                      |
|----------------------|--------------------------------------|
| <b>Massachusetts</b> | : None of the components are listed. |
| <b>New York</b>      | : None of the components are listed. |
| <b>New Jersey</b>    | : None of the components are listed. |
| <b>Pennsylvania</b>  | : None of the components are listed. |

### California Prop. 65

This product does not require a Safe Harbor warning under California Prop. 65.

### International regulations

#### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

#### Montreal Protocol

Not listed.

#### Stockholm Convention on Persistent Organic Pollutants

Not listed.

#### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

#### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

## Section 16. Other information

### Hazardous Material Information System (U.S.A.)

|                  |   |   |
|------------------|---|---|
| Health           | / | 0 |
| Flammability     |   | 0 |
| Physical hazards |   | 0 |

**Caution: HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. Although HMIS® ratings and the associated label are not required on SDSs or products leaving a facility under 29 CFR 1910.1200, the preparer may choose to provide them. HMIS® ratings are to be used with a fully implemented HMIS® program. HMIS® is a registered trademark and service mark of the American Coatings Association, Inc.**

This document contains proprietary information. It must not be reproduced or disclosed to others without prior written approval. The user is responsible for checking the current effective date before using this document.

|                                                                                     |                                        |                                      |
|-------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------|
| <b>SDS Title:</b><br>Norepinephrine Bitartrate Injection, 4mg/4ml Safety Data Sheet | <b>SDS Number:</b><br>SDS-000094       | <b>Page Number:</b><br>Page 14 of 14 |
| <b>Function:</b><br>Regulatory Affairs                                              | <b>Effective Date:</b><br>May 29, 2026 | <b>Version number:</b><br>2.0        |

## Section 16. Other information

The customer is responsible for determining the PPE code for this material. For more information on HMIS® Personal Protective Equipment (PPE) codes, consult the HMIS® Implementation Manual.

### National Fire Protection Association (U.S.A.)



### Procedure used to derive the classification

| Classification  | Justification |
|-----------------|---------------|
| Not classified. |               |

### History

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Date of issue/Date of revision</b> | : 05/29/2026                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Date of previous issue</b>         | : 05/31/2024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Version</b>                        | : 2.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Key to abbreviations</b>           | : ATE = Acute Toxicity Estimate<br>BCF = Bioconcentration Factor<br>GHS = Globally Harmonized System of Classification and Labelling of Chemicals<br>IATA = International Air Transport Association<br>IBC = Intermediate Bulk Container<br>IMDG = International Maritime Dangerous Goods<br>IMO = International Maritime Organization<br>LogPow = logarithm of the octanol/water partition coefficient<br>MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution)<br>N/A = Not available<br>SGG = Segregation Group<br>TDG = Transportation of Dangerous Goods<br>UN = United Nations |
| <b>References</b>                     | : HCS (U.S.A.)- Hazard Communication Standard<br>International transport regulations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

Indicates information that has changed from previously issued version.

### Notice to reader

To the best of our knowledge, the information contained herein is accurate. However, neither the above-named supplier, nor any of its subsidiaries, assumes any liability whatsoever for the accuracy or completeness of the information contained herein.

Final determination of suitability of any material is the sole responsibility of the user. All materials may present unknown hazards and should be used with caution. Although certain hazards are described herein, we cannot guarantee that these are the only hazards that exist.